Search

This article provides information about a clinical trial for the treatment of acute myeloid leukemia (AML). The trial is currently recruiting participants and aims to evaluate the effectiveness of a modified MAV regimen, which includes the drugs Mitoxantrone hydrochloride liposome, Cytarabine, and Venetoclax. The trial is open to individuals aged 60-70 years who have been newly diagnosed with primary AML. The study is being conducted in China by the First Affiliated Hospital of Zhejiang University, in collaboration with CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. [Extracted from the article]

This document provides information about a clinical trial for the treatment of relapsed/refractory acute myeloid leukemia (AML). The trial is currently recruiting participants and aims to evaluate the effectiveness of a treatment regimen called MAV, which combines mitoxantrone hydrochloride liposome injection, cytarabine, and venetoclax. The eligibility criteria for participants are outlined, and the trial is being conducted in China. The document also includes administrative information such as the study ID number and the contact information for the primary investigator. [Extracted from the article]

In a single-center study involving 134 children with acute promyelocytic leukemia (APL), a case was described where a child exhibited a lack of efficacy with tretinoin and arsenic-trioxide treatment. The child had previously received a different treatment protocol and started receiving tretinoin and arsenic-trioxide for APL. Unfortunately, the child was resistant to these treatments and ultimately died due to the progression of APL. [Extracted from the article]

A 66-year-old woman with histiocytic sarcoma experienced severe myelosuppression and lack of efficacy during treatment with ifosfamide, mitoxantrone, vincristine, etoposide, and prednisone. She initially received a poly-chemotherapy induction regimen followed by consolidation therapy with high-dose chemotherapy. However, she developed severe myelosuppression and showed no improvement in her condition. She was then treated with pembrolizumab in combination with a GDP regimen, which resulted in an effective response. After experiencing severe thrombocytopenia, she was treated with sintilimab and thalidomide and remained symptom-free in complete remission for over 4 years. [Extracted from the article]

In a study conducted between December 2019 and January 2024, a woman with a history of acute myeloid leukemia (AML) underwent treatment with cytarabine and mitoxantrone. Despite ongoing treatment, she experienced a relapse of AML at 11 months. This case report highlights a lack of efficacy of cytarabine and mitoxantrone in treating AML in this particular patient. [Extracted from the article]

A patent application titled "Tobacco Mosaic Virus Delivery Of Mitoxantrone For Cancer Therapy" has been published online. The application describes a method of treating cancer using a rod-shaped plant virus particle loaded with mitoxantrone (MTO) or an analog thereof. The virus particle can be administered to a tumor site or systemically, and release of the MTO is pH dependent and triggered by an acidic tumor microenvironment. The method is particularly relevant for treating breast cancer, including metastatic and triple negative breast cancer. Additional anticancer agents or therapies can also be administered in conjunction with the virus particle. [Extracted from the article]

A recent report from the University of Crete discusses the potential use of novel drugs in the treatment of ovarian cancer. The researchers designed and synthesized two high-affinity GnRH-R agonists, Con-3 and Con-7, which were covalently coupled with the DNA synthesis inhibitor mitoxantrone. The study found that treatment with Con-3 and Con-7 resulted in the accumulation of mitoxantrone within ovarian cancer cells, leading to increased apoptosis and reduced proliferation. These findings suggest that Con-3 and Con-7 could be promising lead compounds for the development of anticancer drugs targeting ovarian tumors. [Extracted from the article]

A 27-year-old woman developed isolated hyperphosphataemia during chemotherapy for acute myeloid leukemia. She presented with thrombocytopenia and leukopenia and was diagnosed with acute myeloid leukemia. Her serum phosphate levels increased during treatment and she was diagnosed with hyperphosphataemia. She was treated with phosphate binders to maintain normal levels. The chemotherapy drugs were attributed to the development of hyperphosphataemia. [Extracted from the article]

A recent report from researchers at the School of Life Sciences in Changsha, People's Republic of China, discusses the potential therapeutic effects of mitoxantrone on ineffective erythropoiesis in β-thalassemia. β-thalassemia is a genetic condition characterized by reduced or absent synthesis of β-globin, leading to expanded and ineffective erythropoiesis. Mitoxantrone, an antitumor agent, was found to decrease α-globin precipitates and improve anemia, splenomegaly, and ineffective erythropoiesis in a mouse model of β-thalassemia intermedia. The researchers suggest that targeting autophagy may be a novel therapeutic approach for β-thalassemia. This research has been peer-reviewed. [Extracted from the article]

Researchers from Soochow University in Suzhou, China have developed a drug delivery platform using lithium-doped bioactive glass microspheres (7Li-MBGs) to improve the treatment of multiple myeloma (MM). The 7Li-MBGs have a mesoporous structure and high specific surface area, allowing for enhanced drug release and bioactive response. The platform effectively releases drugs in the long-term, repairs bone defects, inhibits bacterial growth, and improves tumor cell activity. This research provides new ideas for the treatment of MM. [Extracted from the article]

A recent study conducted at University Hospital Dresden in Germany explored the use of venetoclax, a BCL-2 inhibitor, in combination with high-dose cytarabine and mitoxantrone as a salvage treatment for relapsed or refractory acute myeloid leukemia (AML). The study found that this combination therapy was well-tolerated and highly effective, resulting in complete remissions in 81.6% of patients. The safety and efficacy of this treatment approach compared favorably to other regimens, providing a less intense option for fit patients with relapsed or refractory AML. Further research and updated results are ongoing. [Extracted from the article]

Researchers from China Medical University have developed a quantum computational model to analyze drug delivery. Specifically, they studied the co-loading of mitoxantrone (MTX) and human beta-defensin 3 (HBD3) onto composite polymers. The study found that MTX strongly interacts with PLGA, while HBD3 interacts strongly with CHI. The researchers concluded that these molecular results can be used to design polymeric carriers for drug delivery. This research has been peer-reviewed and published in the Journal of Molecular Liquids. [Extracted from the article]

A retrospective study of 88 patients with acute promyelocytic leukemia found that one patient experienced cardiac toxicity in the form of mild premature ventricular beats while being treated with arsenic-trioxide, mitoxantrone, and tretinoin. The patient received intravenous arsenic-trioxide, tretinoin, and mitoxantrone over a period of 28 days, but the duration of treatment and outcome were not specified. This case highlights the potential cardiac side effects of these medications in the treatment of acute promyelocytic leukemia. [Extracted from the article]

A 31-year-old man with mast cell activation (MCA) and mast cell leukemia (MCL) exhibited lack of efficacy and acquired drug resistance during treatment with various medications. He initially received epinephrine, diphenhydramine, cetirizine, famotidine, and dexamethasone for MCA, but remained symptomatic. He then received avapritinib, cladribine, imatinib, and midostaurin for MCL, but showed no improvement. Despite undergoing peritoneal catheter placement and receiving IV epinephrine, he experienced severe hypotensive events and developed acquired drug resistance to chemotherapy. Omalizumab provided temporary relief, but he ultimately died due to MCL progression. [Extracted from the article]

This document provides information about a clinical trial, NCT06475287, that aims to investigate the effectiveness and safety of a combination therapy for second-line treatment of advanced hepatocellular carcinoma (HCC). The trial involves the use of hepatic arterial infusion chemotherapy (HAIC) combined with TQB2450 and anlotinib. The study is expected to be completed by July 2025 and is taking place in China. The document includes administrative details such as the NCT number and collaborating institutions. [Extracted from the article]

A study conducted by researchers at Capital Medical University in Beijing, China, explored the use of liposomal mitoxantrone (Lipo-MIT) in combination therapy for patients with relapsed/refractory NK/T-cell lymphoma (NKTCL). The study included 12 patients who had previously received pegaspargase-based treatments. The results showed that the combination therapy based on Lipo-MIT had a high remission rate, with complete response (CR) in 41.7% of patients and partial response in 41.7% of patients. However, the duration of remission needs to be further extended. Side effects, such as myelosuppression and skin hyperpigmentation, were reported in all patients. The study concluded that active supportive therapy should be given when combining Lipo-MIT with other cytotoxic drugs. [Extracted from the article]

This document provides information about a clinical trial being conducted in China by the Institute of Hematology & Blood Diseases Hospital. The trial aims to study the effectiveness of a treatment regimen called VMAC+DLI for patients with acute myeloid leukemia (AML) who have experienced a recurrence after undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The treatment regimen includes the drugs Veneclatra, Mitoxantrone Liposomal, Cytosine arabinoside, and Cyclophosphamide. The trial is currently recruiting participants, and the estimated completion date is October 31, 2027. The document also provides contact information for the primary and backup contacts for the trial. [Extracted from the article]

A 23-year-old man with acute lymphoblastic leukemia did not respond to treatment with cytarabine and mitoxantrone. The man initially underwent induction treatment in 2017, but his symptoms worsened in 2022, leading to the administration of cytarabine and mitoxantrone. However, the treatment was ineffective. The man sought a second medical opinion in Spain and was subsequently diagnosed with a carbapenem-resistant Pseudomonas aeruginosa infection. [Extracted from the article]

A recent report from the University of Rey Juan Carlos in Madrid, Spain discusses the potential use of mesoporous silica nanoparticles (MSNs) as a drug delivery system for breast cancer treatment. The researchers developed a method to increase drug loading capacity and prevent premature drug release by using a drug structure-directing agent (DSDA) derived from the anticancer drug mitoxantrone. The MSNs filled with the mitoxantrone prodrug showed pH-dependent drug release, with minimal release at physiological pH and increased release in the tumor microenvironment. The study demonstrated the efficacy of these magnetic MSNs in reducing breast cancer cell viability, suggesting their potential as an efficient and targeted drug delivery system for breast cancer treatment. [Extracted from the article]

A study conducted at Shahid Beheshti University in Tehran, Iran, has focused on the development of a nanocarrier system based on carbon quantum dots (CQDs) for the efficient delivery of the cancer drug mitoxantrone (MTX). The N-doped CQDs were synthesized and loaded with MTX, resulting in an increase in size and high drug entrapment efficiency. The drug release investigation showed pH-dependent improvement, and the N-doped CQD-MTX complex demonstrated a significant effect on MCF-7 breast cancer cells. The researchers concluded that this newly developed drug delivery complex could provide a similar influence on cancer cells as free MTX while improving the pharmacokinetics of the drug. [Extracted from the article]

A recent study conducted by researchers at Chongqing University Three Gorges Hospital in China explored the use of liposomal mitoxantrone-based multidrug chemotherapy as a potential treatment for relapsed/refractory acute lymphoblastic leukemia (ALL). The researchers presented a case study of a patient with R/R ALL who responded well to this treatment, achieving a rapid complete response after 35 days of therapy. The patient was subsequently treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) and remained leukemia-free at the 5-month follow-up. The study suggests that liposomal mitoxantrone-based multidrug chemotherapy could be further investigated as a bridge to allo-HSCT in patients with R/R ALL. [Extracted from the article]

A report from Cleveland Clinic discusses the efficacy and safety of the salvage chemotherapy regimen, Mitoxantrone, Etoposide, and Cytarabine (MEC), for the treatment of relapsed or refractory Acute Myeloid Leukemia (AML). The study found that MEC was effective in achieving complete remission or complete remission with incomplete hematologic recovery in 51.7% of patients. Patients with lower disease burden at the start of treatment were more likely to achieve remission. However, common side effects of MEC included febrile neutropenia, infections, and severe oral mucositis. The study suggests that MEC is a viable option for patients with relapsed or refractory AML, particularly those with low disease burden. [Extracted from the article]

A recent study conducted at the University of Glasgow in the United Kingdom evaluated the effectiveness and tolerability of a chemotherapy protocol called CMOP for the treatment of feline intermediate-large cell lymphoma. The study found that the overall response rate was 74%, with 45% of cats achieving complete remission. Cats that responded to treatment had longer progression-free intervals and median survival times compared to non-responders. The study concluded that cats that respond to treatment, particularly those that achieve complete remission, are likely to have more durable responses. The CMOP protocol was found to be an alternative and well-tolerated treatment for cats with this type of lymphoma. [Extracted from the article]

A study conducted at Rambam Health Care Campus in Haifa, Israel compared the efficacy of liposomal daunorubicin (DNX) and mitoxantrone in the induction of pediatric acute myeloid leukemia (AML). The study aimed to assess measurable residual disease (MRD) using flow cytometry after induction therapy and to stratify patients based on their response to treatment. The results showed that mitoxantrone had a superior anti-leukemic effect compared to liposomal daunorubicin. The study concluded that intensifying induction therapy and using risk stratification based on response to treatment improved outcomes for pediatric AML patients. [Extracted from the article]

A study conducted from January 2008 to December 2022 described 22 patients, including 3 girls and 5 boys, who developed various toxicities during treatment with daunorubicin, mitoxantrone, or tretinoin for acute promyelocytic leukemia. These toxicities included pseudotumor cerebri, skin rash, differentiation syndrome, moderate systo-diastolic dysfunction, and mild pulmonary insufficiency. The patients received different treatment regimens, and some also had comorbidities. However, after receiving unspecified treatment, the toxicities resolved and the patients continued their therapy. Cardiological evaluation revealed that three patients developed moderate systo-diastolic dysfunction and mild pulmonary insufficiency due to daunorubicin and mitoxantrone. [Extracted from the article]

A study conducted by investigators at Chongqing Medical University in China has developed and validated a new high-performance liquid chromatography-ultraviolet assay for quantifying mitoxantrone in the plasma of mice. The method was found to be simple, rapid, sensitive, and accurate, making it suitable for determining the content of mitoxantrone in mouse plasma after tail vein injection. The research provides valuable insights into the field of chromatographic science and its applications in the medical field. [Extracted from the article]

A patent application has been submitted for the use of mitoxantrone hydrochloride liposome in the treatment of ovarian cancer, gastric cancer, and head and neck squamous cell carcinoma. The application emphasizes the need for improved treatment options for these difficult-to-treat cancers. The patent application provides details about the properties of the medication, including the size of the liposome particles and the composition of the phospholipid bilayer. It also discusses the specific types of cancer that can be treated and the potential methods of administering the medication. [Extracted from the article]

Researchers from the University of Bradford have conducted a study on the encapsulation and delivery of the drug Mitoxantrone (MTX) using zirconium-based metal-organic frameworks (MOFs) for breast cancer treatment. The study found that the MOFs UiO-66 and UiO-66-NH2 had loading capacities of 40% and 21% for MTX, respectively. The MOFs demonstrated a controlled release of MTX, with UiO-66-NH2-MTX showing a more sustained release. The study also assessed the antiproliferative activity of the MTX-loaded MOFs on breast cancer cell lines and found that they had a slower release profile but a higher IC50 value compared to free MTX. These findings suggest that MTX-loaded MOFs have the potential to be an alternative formulation to mitigate side effects. [Extracted from the article]

A report from the University of Science and Technology China discusses research on the development of a self-supply reactive oxygen species-responsive polyprodrug for enhanced chemotherapy. The researchers designed a polyprodrug that releases a chemotherapy drug called mitoxantrone in response to reactive oxygen species in the tumor microenvironment. This design reduces systemic toxicity and enhances the efficacy of the chemotherapy drug. The research demonstrates promising results in addressing the limitations associated with mitoxantrone therapy. [Extracted from the article]

A study conducted at Saratov State University in Russia explored the effects of an extremely low frequency alternating magnetic field (ELF AMF) on breast cancer cells. The researchers found that exposure to an alternating magnetic field of 100 mT in a pulsed mode with a frequency of 95 Hz led to the suppression of cell proliferation and survival. The study also utilized Brillouin light scattering (BLS) spectrometry to analyze the presence of magnetic nanocarriers in the cells. The research concluded that the magnetic carriers were safe in terms of the release of their constituent ions. [Extracted from the article]

A 48-year-old man developed an Aeromonas hydrophila infection and psychiatric symptoms while undergoing treatment for acute myeloid leukemia. The infection occurred after sustaining puncture wounds to his hand while fishing. The man received treatment with cytarabine, mitoxantrone, and levofloxacin, and his symptoms improved after discontinuing levofloxacin and receiving ceftazidime. After four months of treatment, his hand wound healed. [Extracted from the article]

This article provides information about a clinical trial in China that is currently recruiting participants. The trial aims to evaluate the effectiveness of a treatment regimen for patients with B-cell acute lymphoblastic leukemia and B-cell lymphoma refractory. The regimen includes mitoxantrone hydrochloride liposome injection-based bridging therapy, fludarabine-based chemotherapy, and CD19 CAR-T cells. The study will assess various factors such as overall response rate, complete response rate, in vivo expansion and survival of CD19 CAR-T cells, and the incidence of treatment-related adverse events. The goal of the trial is to improve patient outcomes and provide effective CAR-T cell therapy for hematologic malignancies. [Extracted from the article]

A recent study conducted by researchers at Huazhong University of Science and Technology in Wuhan, China, has developed a new method to improve the bioavailability of the anticancer drug Mitoxantrone (MIT) for breast cancer treatment. The researchers synthesized ultrasmall ferric ion coupled mitoxantrone nanoparticles (Fe-MIT NPs) that exhibited good dispersion and prolonged circulation in the bloodstream. These nanoparticles showed a high degree of accumulation within tumors and had a notable chemotherapy effect on cancer cells by increasing intracellular levels of reactive oxygen species (ROS). The loaded Fe3+ within the nanoparticles initiated ferroptosis, a form of cell death, and their small size enabled better penetration of tumors. The study concluded that Fe-MIT NPs delivered superior anticancer benefits compared to free MIT. [Extracted from the article]

A research report from Ardabil University of Medical Sciences in Iran discusses the intercalation of the anticancer drug Mitoxantrone (MTX) into DNA. The study used spectral fluorescence spectroscopy and surface plasmon resonance (SPR) methods to evaluate the binding strength of MTX to DNA. The results showed that hydrogen bonding was the major binding force for the complexation of MTX to DNA, and the study concluded that hydrogen bonding is the main mechanism for the intercalation of MTX into DNA. This research provides valuable insights into the interaction between anticancer drugs and DNA. [Extracted from the article]

A study conducted at N.G. Chernyshevsky Saratov State University in Saratov, Russia, explores the challenges and trends in measuring the concentration of the anthracycline antibiotic mitoxantrone (MTX) in biofluids and new pharmaceutical systems. The research emphasizes the importance of monitoring the concentration of cytostatic drugs, such as MTX, due to their high toxicity. The study critically evaluates existing methods for determining MTX concentration and their application in monitoring. The research was supported by the Russian Science Foundation and has been peer-reviewed. For more information, readers can contact the authors at N.G. Chernyshevsky Saratov State University. [Extracted from the article]

A pilot study conducted at Capital Medical University in Beijing, China, explored the efficacy and safety of a treatment regimen consisting of mitoxantrone hydrochloride liposome, bortezomib, and dexamethasone (MVD) in multiple myeloma (MM) patients with extramedullary plasmacytoma (EMP). The study enrolled 15 patients with EMP and found that the overall response rate (ORR) of EMP was 53.3%, and the hematological ORR was 77.8%. The most common adverse effects were myelosuppression and respiratory infection. The study concluded that the MVD-based regimen showed promising early response and efficacy in MM with EMP and should be further explored in prospective phase 2 studies. [Extracted from the article]

A recent study conducted by researchers at Bursa Uludag University in Turkey compared the effectiveness of different anthracycline drugs (idarubicin, daunorubicin, and mitoxantrone) for induction chemotherapy in patients with acute myeloid leukemia (AML). The study included 317 newly diagnosed AML patients and found that there was no significant difference in overall survival between the three anthracycline treatment groups. The study also noted that the choice of anthracycline for induction chemotherapy in AML is becoming more challenging due to the evolving treatment landscape in patients with targetable mutations. These findings align with previous studies and provide valuable insights for clinicians treating AML patients. [Extracted from the article]

Researchers at Ohio State University have made new findings on anticancer agents. They have described the characteristics of a vase-shaped basket that can form an inclusion complex with the anticancer drug mitoxantrone. The basket has a deep nonpolar pocket and is able to include mitoxantrone, reducing its cytotoxicity. The researchers believe that these deep-cavity baskets hold promise for developing antidotes against a range of aromatic toxicants in complex biological systems. [Extracted from the article]

A recent study conducted at Capital Medical University in Beijing, China, explored the combination of Mitoxantrone Hydrochloride Liposome (PLM60) with Tislelizumab in patients with relapsed or refractory NK/T cell lymphoma. The study aimed to assess the safety and efficacy of this combination therapy. The results showed that PLM60 plus Tislelizumab demonstrated promising efficacy with manageable safety profiles in patients with relapsed or refractory NK/T cell lymphoma. Further research is needed to determine long-term outcomes such as progression-free survival and overall survival. [Extracted from the article]

A recent study conducted by researchers at the Dana-Farber Cancer Institute in Boston, Massachusetts, explored the use of Lenalidomide in combination with Mitoxantrone, Etoposide, and Cytarabine (MEC) for patients with relapsed or refractory acute myeloid leukemia (R/R AML). The study found that this combination therapy resulted in a high response rate and improved overall survival compared to historical controls. However, some patients did experience early hepatic toxicity. The researchers recommend further evaluation of high-dose Lenalidomide combined with MEC in a randomized study. [Extracted from the article]

A recent study conducted at Cangzhou Central Hospital explored the relationship between inflammation and cancer development, with a focus on non-small cell lung cancer (NSCLC). The researchers analyzed RNA sequencing data from 1014 lung cancer samples and identified 200 inflammatory-related genes. They constructed a prognosis prediction model based on these genes, which showed promise in distinguishing high-risk NSCLC cases with poor prognostic outcomes. Additionally, the study found that different risk groups based on the inflammatory-related gene signature were associated with varying sensitivity to chemotherapy and immunotherapy. The researchers also investigated the potential of targeting the KRT6A gene to enhance the sensitivity of NSCLC cells to mitoxantrone and oxaliplatin. Overall, this study suggests that inflammatory-related genes could serve as biomarkers for NSCLC treatment and highlights the importance of personalized approaches in cancer therapy. [Extracted from the article]

A recent study conducted by researchers at Ulsan National Institute of Science and Technology (UNIST) in South Korea has focused on the role of epigenetic dysregulation in cancer initiation and progression. The researchers developed a screening system to identify novel TET activators, which are proteins involved in DNA methylation-demethylation dynamics. Through their experiments, they found that mitoxantrone, a compound provided by the National Cancer Institute, exhibited potent TET agonist activity and increased levels of 5-hydroxymethylcytosine (5hmC), a modified form of DNA. The study suggests that mitoxantrone has the potential to induce tumor cell death through the restoration of TET activity, opening up possibilities for targeted epigenetic therapies in cancer treatment. [Extracted from the article]

A recent study conducted at Shahrekord University in Iran has explored the use of nano-carriers to enhance the delivery and effectiveness of drugs in cancer chemotherapy. The researchers co-loaded silymarin and metformin into mesoporous silica nanoparticles (MSNs) and evaluated their synergistic inhibitory effect on breast cancer cells. The study found that the co-loaded MSNs increased the sensitivity of the cells to mitoxantrone chemotherapy and reduced colony formation. The researchers concluded that using MSNs as a drug delivery system enhances the anti-cancer effects of both metformin and silymarin against breast cancer cells. [Extracted from the article]

The collateral sensitivity effect is among the most promising strategies for overcoming multidrug resistance in cancer. In this work, 28 cucurbitane-type triterpenoids (1-28), previously isolated from the African medicinal plant Momordica balsamina and its derivatives, were evaluated for their collateral sensitivity effect on three different human cancer entities, gastric (EPG85-257), pancreatic (EPP85-181), and colon (HT-29), each with two different multidrug-resistant variants. One was selected for its resistance to daunorubicin (EPG85-257RDB, EPP85-181RDB, HT-29RDB) and the other was selected for its resistance to mitoxantrone (EPG85-257RNOV, EPP85-181RNOV, HT-29RNOV). On gastric cell lines, the best results were obtained for compounds 3 and 10, which exhibited a collateral sensitivity effect together with high antiproliferative activity. In turn, on colon cancer cell lines, the best multidrug resistance-selective antiproliferative effects were observed for derivatives 11, 13, and 15, which showed collateral sensitivity effects against both resistant variants. Compounds 11 and 3 were also the most selective against the multidrug resistance pancreatic cells lines. Some compounds, such 6, 10, 11 and 15, were previously found to be strong P-glycoprotein modulators, thus highlighting their potential as promising leads for overcoming multidrug resistance in cancer cells. [ABSTRACT FROM AUTHOR]

A case report published in Reactions Weekly describes a 54-year-old woman with systemic mastocytosis and multiple sclerosis (MS) who exhibited lack of efficacy during treatment with methylprednisolone and mitoxantrone. The woman experienced severe cognitive dysfunction despite high-dose methylprednisolone, and her brain MRI showed an increase in lesion load. Mitoxantrone infusions also did not have the desired effect, as brain MRI showed new active lesions. The woman's treatment was switched to cladribine, which resulted in stable physical examination and brain MRI findings. [Extracted from the article]

Keywords: Beijing; People's Republic of China; Asia; Alkylating Agents; Anthraquinones; Antibiotics; Antigens; Antineoplastics; Antiparasitics; Biological Factors; CD Antigens; Cancer; Cell Adhesion Molecules; Cell Research; Chlorine Compounds; Cisplatin Therapy; Drug Delivery; Drug Delivery Systems; Drugs and Therapies; Emerging Technologies; Fucoidan Therapy; Glycoproteins; Health and Medicine; Immunology; Lectins; Membrane Glycoproteins; Membrane Proteins; Mitoxantrone; Mitoxantrone Therapy; Nanogels; Nanotechnology; Nitrogen Compounds; Oncology; P-Selectin; Pharmaceuticals; Platelet Membrane Glycoproteins; Platinum Compounds; Proteins; Radiotherapy; Selectins EN Beijing People's Republic of China Asia Alkylating Agents Anthraquinones Antibiotics Antigens Antineoplastics Antiparasitics Biological Factors CD Antigens Cancer Cell Adhesion Molecules Cell Research Chlorine Compounds Cisplatin Therapy Drug Delivery Drug Delivery Systems Drugs and Therapies Emerging Technologies Fucoidan Therapy Glycoproteins Health and Medicine Immunology Lectins Membrane Glycoproteins Membrane Proteins Mitoxantrone Mitoxantrone Therapy Nanogels Nanotechnology Nitrogen Compounds Oncology P-Selectin Pharmaceuticals Platelet Membrane Glycoproteins Platinum Compounds Proteins Radiotherapy Selectins 620 620 1 11/06/23 20231107 NES 231107 2023 NOV 7 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Cancer is now available. The news correspondents obtained a quote from the research from Peking Union Medical College Hospital, "Tumoral P-selectin can be rapidly upregulated after ionization radiation, indicating it is a highly selective target for drug delivery. [Extracted from the article]

For more information on this research see: Case Report: A recurrent case of ALK-ALCL after autologous transplantation was successfully treated with BV + a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome with the addition of chidamide maintenance therapy. Keywords: Anthraquinones; Antibiotics; Antineoplastics; Biotechnology; Bone Research; Chemotherapy; Drug Delivery Systems; Drugs and Therapies; Health and Medicine; Liposomes; Mitoxantrone; Mitoxantrone Therapy; Pharmaceuticals EN Anthraquinones Antibiotics Antineoplastics Biotechnology Bone Research Chemotherapy Drug Delivery Systems Drugs and Therapies Health and Medicine Liposomes Mitoxantrone Mitoxantrone Therapy Pharmaceuticals 649 649 1 10/16/23 20231016 NES 231016 2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- New study results on liposomes have been published. [Extracted from the article]